NEUMORA THERAPEUTICS, INC. (NMRA) Debt / Equity
- 2026-06-30: Debt/Equity Ratio 2.54.
- 2026-03-31: Debt/Equity Ratio 1.6.
- 2025-12-31: Debt/Equity Ratio 1.1.
- 2025-09-30: Debt/Equity Ratio 0.3.
Complete source-backed debt/equity ratio history.
- Available history
- 2025-06-30 to 2026-06-30
- Data captured
Historical Debt/Equity Ratio
| Date | Debt/Equity Ratio |
|---|---|
| 2026-06-30 | 2.54 |
| 2026-03-31 | 1.6 |
| 2025-12-31 | 1.1 |
| 2025-09-30 | 0.3 |
| 2025-06-30 | 0.22 |
Annual Debt/Equity Ratio
| Date | Debt/Equity Ratio |
|---|---|
| 2025-12-31 | 1.1 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |